Post hoc AHA 2026 data show the oral GLP-1 receptor agonist lowered systolic blood pressure across hypertension stages, partly beyond weight loss.
|Articles|January 13, 2022
Daily OTC Pearl: Nikzon Hemorrhoidal
Author(s)Saro Arakelians, PharmD
Nikzon Hemorrhoidal may temporarily relieve itching, burning, and discomfort associated with hemorrhoids.
Advertisement
OTC/Lifestyle Pearl of the Day: Nikzon Hemorrhoidal
Indication: Nikzon Hemorrhoidal is used for the temporary relief of anorectal itching, burning, and discomfort associated with hemorrhoids, anorectal disorders, inflamed hemorrhoidal tissues, or piles.
Insight:
- Ingredients: Phenylephrine hydrochloride 2.5 mg in 1 g, pramoxine hydrochloride 10 mg in 1 g.
- For external use only
- Caution: Do not put this product into the rectum by using fingers or any mechanical device or applicator.
- Directions: Remove cap and lift foil safety seal from tube.
- Adults: When practical, cleanse the affected area with mild soap and warm water, and rinse thoroughly. Gently dry by patting or blotting with toilet tissue or a soft cloth before application of this product.
- Apply externally to the affected area with a thin layer up to 4 times daily.
- Children under 12 years of age: consult a physician.
- Storage: Store at room temperature 15°-30°C (59-86°F).
Sources:
Advertisement
Related to this article
Cody Parsons, APh, PharmD, BCCCP, says protected pharmacist access lets patients with heart failure be seen more often than typical clinic visits allow.
The evidence for GLP-1 receptor agonists keeps growing, while access for low-income patients keeps narrowing.
Specialty pharmacists can help patients with cancer weigh the benefits and risks of GLP-1 receptor agonists as use expands and new evidence emerges.
Pharmacists can work alongside dermatologists, nurses, and other health care professionals to help answer skin care–related questions and help patients understand trial outcomes.
Early metformin may curb insulin starts in gestational diabetes, while a separate analysis ties a history of the condition to advanced CKM syndrome.
Pharmacy Times previews enlicitide, survodutide, diet and heart failure risk, and pharmacist-led HF care ahead of the AHA Scientific Sessions in Chicago.
Expected in the first half of 2028, the planned separation would create a stand-alone retail pharmacy company with nearly 30,000 pharmacists.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Understanding Kratom: Pharmacology, Safety, and Regulation
2
How Stanford Pharmacists Help Close Heart Failure Therapy Gaps
3
Orforglipron Lowers Systolic BP in ATTAIN-1, ATTAIN-2 Analyses
4
GLP-1s and Obesity Care: Cardiorenal Outcomes, Prescribing Considerations, and Access Barriers
5